期刊文献+

短期胰岛素泵强化治疗对初发2型糖尿病患者血浆vaspin水平的影响 被引量:9

Effects of short-term continuous subcutaneous insulin infusion on fasting plasma vaspin levels in patients with recent-onset type 2 diabetes mellitus
原文传递
导出
摘要 目的 观察短期胰岛素泵强化治疗对初发2型糖尿病患者血浆内脏脂肪组织来源的丝氨酸蛋白酶抑制物vaspin水平的影响,探讨其与胰岛素敏感性的关系.方法 30例初发2型糖尿病患者使用胰岛素泵强化治疗2周,治疗前后采用高胰岛素-正葡萄糖钳夹术评价其胰岛素敏感性,用酶免法测定血浆vaspin及相关代谢指标.结果 2型糖尿病组空腹血浆vaspin水平高于正常糖耐量(NGT)组和糖调节受损(IGR)组.2型糖尿病组经胰岛素泵强化治疗后葡萄糖代谢率升高[(5.10±0.51对2.99±0.42)mg·kg-1·min-1,P<0.05],稳态模型评估的胰岛素抵抗指数(HOMA-IR)降低[2.30(1.09~7.20)对4.28(1.70~6.47),P<0.05],同时血浆vaspin水平也显著降低[(1.19±0.57对1.83±0.55)ng/ml,P<0.05],且vaspin水平的降低与HOMA-IR的改变呈明显正相关.结论 胰岛素泵强化治疗能有效改善2型糖尿病患者的胰岛素敏感性,降低血浆vaspin水平;且血浆vaspin水平与2型糖尿病患者胰岛索敏感性有关. Objective To investigate the effects of short-term continuous subcutaneous insulin infusion (CSII) on plasma visceral adipose tissue-derived serine protease inhibitor ( vaspin ) levels in patients with recentonset type 2 diabetes mellitus, and to study the association between insulin sensitivity and vaspin levels.Methods Thirty patients with recent-onset type 2 diabetes mellitus were treated with CSII for 2 weeks.Euglycemic-hyperinsulinemic clamps (EHC) were performed to evaluate the insulin sensitivity in type 2 diabetes group. Plasma vaspin levels were measured by an ELISA kit. The association between plasma vaspin levels and metabolic parameters were analyzed. Results Fasting plasma vaspin levels were higher in type 2 diabetes than in impaired glucose regulation and normal glucose tolerance groups [( 1.83±0.55 vs 0. 43±0.21 and 0.56±0.26) ng/ml,P〈0.05]. With CSII,vaspin levels [( 1.19 ±0.57 vs 1.83 ±0.55 ) ng/ml, P〈0.05] and homeostasis model assessment for insulin resistance [HOMA-IR ,2.30 ( 1.09-7.2 ) vs 4.28 ( 1.7-6.47 ), P〈0.05] were significantly decreased,accompanied with an increase in glucose metabolic rate [(5. 10±0.51 vs 2.99±0.42 )mg·kg-1·min-1 ,P〈0.05] in type 2 diabetes group. Changes in circulating vaspin concentrations were correlated positively with changes in HOMA-IR. Conclusion In type 2 diabetic patients,elevated plasma vaspin levels are significantly decreased after CSII treatment. Vaspin may play a role in improving insulin sensitivity of diabetic humans.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2010年第12期1027-1030,共4页 Chinese Journal of Endocrinology and Metabolism
基金 基金项目:国家自然科学基金项目(30771037、30871199、30971388)
关键词 丝氨酸蛋白酶抑制物 糖尿病 2型 持续性皮下胰岛素输注 高胰岛素-正葡萄糖钳夹术 Serine protease inhibitor Diabetes mellitus, type 2 Continuous subcutaneous insulin infusion Euglycemic-hyperinsulinemic clamp
  • 相关文献

参考文献1

二级参考文献14

  • 1Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, et al. Mefformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008; 57: 1501-1507.
  • 2Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009; 160: 65-70.
  • 3Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-377.
  • 4Kloting N, Berndt J, Kralisch S, Kovacs E Fasshauer M, Schon MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436.
  • 5Gonzalez-Ortiz M, Martinez-Abundis E. Comparison of several formulas to assess insulin action in the fasting state with the hyperglycemic-hyperinsulinemic clamp technique in healthy individuals. Rev Invest Clin 2003; 55:419-422.
  • 6Bao Y, Lu J, Wang C, Yang M, Li H, Zhang X, et al. Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 2008; 201: 378-384.
  • 7World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complication. WHO/NCD/NCS 1999: 31-33. (Accessed at http://whqlibdoc. who. int/hq/1999/WHO_NCD_NCS_99. 2.pdj-').
  • 8WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
  • 9Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247-251.
  • 10Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18: 240-245.

共引文献39

同被引文献54

引证文献9

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部